Lincoln International’s Global Healthcare Group Announces Strong Results in 2022
Lincoln International’s global Healthcare Group enjoyed another consecutive year of record-setting mergers and acquisitions (M&A) deal volume, average deal size and a record backlog heading in to 2023. Our performance is especially notable given global healthcare M&A volumes saw a modest pull back in 2022 brought on by instability in the labor market, higher inflation and interest rates, pressure on reimbursements and the waning influence of COVID-19-era government-funded supports.
Despite these macro influences, we expect 2023 to be another active year for healthcare dealmaking as industry players and private equity utilize M&A as a strategy to keep pace with the ever-increasing complexities across healthcare access, quality and cost; regulatory pressures; reimbursement rates; software and technology integration; payment reforms and advances in pharma and medical technology.
Our team has deep domain expertise and transaction experience across a number of high growth areas of the global healthcare economy including:
- Animal health
- Behavioral and mental health
- Fertility and women’s health
- Healthcare IT and tech-enabled services
- Home and community based care
- Labs and lab services
- Payor services and employer-funded insurance services
- Pharma and medtech outsourcing
- Physical / occupational / speech therapy and rehab
- Physician services and ambulatory care
- Value-based care enablement
- Revenue cycle management
Summary
- Lincoln International's Global Healthcare Group announces strong results in 2022.
